BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $121,591,603 | -34.7% | 1,786,273 | -21.7% | 3.05% | -6.7% |
| Q2 2023 | $186,288,150 | +8.0% | 2,282,104 | -1.8% | 3.26% | +7.6% |
| Q1 2023 | $172,444,120 | -22.3% | 2,324,358 | -13.2% | 3.03% | -30.4% |
| Q4 2022 | $222,008,335 | +28.1% | 2,678,672 | +338.8% | 4.36% | +30.0% |
| Q3 2022 | $173,372,000 | -23.7% | 610,466 | -6.9% | 3.35% | -14.1% |
| Q2 2022 | $227,276,000 | -37.5% | 655,654 | -22.0% | 3.90% | -18.7% |
| Q1 2022 | $363,810,000 | -21.1% | 840,131 | -5.7% | 4.80% | -3.8% |
| Q4 2021 | $461,046,000 | -5.4% | 891,186 | -11.3% | 4.99% | -9.5% |
| Q3 2021 | $487,127,000 | -0.4% | 1,005,277 | -7.4% | 5.52% | -3.0% |
| Q2 2021 | $489,041,000 | +20.2% | 1,086,131 | +2.0% | 5.69% | +7.5% |
| Q1 2021 | $406,833,000 | +31.8% | 1,065,202 | +9.6% | 5.29% | +21.6% |
| Q4 2020 | $308,742,000 | +64.3% | 972,263 | +28.2% | 4.35% | +11.4% |
| Q3 2020 | $187,870,000 | +37.1% | 758,367 | +46.1% | 3.91% | +7.1% |
| Q2 2020 | $137,038,000 | +77.3% | 518,944 | +27.3% | 3.65% | +9.4% |
| Q1 2020 | $77,300,000 | – | 407,655 | – | 3.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |